Does ENCORAFENIB Cause Neoplasm recurrence? 21 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Neoplasm recurrence have been filed in association with ENCORAFENIB (BRAFTOVI). This represents 0.3% of all adverse event reports for ENCORAFENIB.
21
Reports of Neoplasm recurrence with ENCORAFENIB
0.3%
of all ENCORAFENIB reports
1
Deaths
4
Hospitalizations
How Dangerous Is Neoplasm recurrence From ENCORAFENIB?
Of the 21 reports, 1 (4.8%) resulted in death, 4 (19.0%) required hospitalization.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENCORAFENIB. However, 21 reports have been filed with the FAERS database.
What Other Side Effects Does ENCORAFENIB Cause?
Death (1,004)
Off label use (989)
Nausea (758)
Fatigue (685)
Diarrhoea (574)
Neoplasm progression (548)
Pyrexia (539)
Product use in unapproved indication (506)
Vomiting (429)
Rash (414)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
PALBOCICLIB (248)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
Which ENCORAFENIB Alternatives Have Lower Neoplasm recurrence Risk?
ENCORAFENIB vs ENDOXAN
ENCORAFENIB vs ENDOXAN BAXTER
ENCORAFENIB vs ENDOXAN INJ
ENCORAFENIB vs ENDOXAN , POUDRE POUR
ENCORAFENIB vs ENFORTUMAB VEDOTIN